ORIGINAL ARTICLE

Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome

N Kaushik, D Fear, S C M Richards, C R McDermott, E F Nuwaysir, P Kellam, T J Harrison, R J Wilkinson, D A J Tyrrell, S T Holgate, J R Kerr

See end of article for authors' affiliations
....

Correspondence to:
Dr J R Kerr, Department of Paediatric Infectious Diseases, Imperial College London, 2nd Floor, Medical School Building, Norfolk Place, London W2 1PG, UK; j.kerr@imperial. ac.uk

Background: Chronic fatigue syndrome (CFS) is a multisystem disease, the pathogenesis of which remains undetermined.

Aims: To test the hypothesis that there are reproducible abnormalities of gene expression in patients with CFS compared with normal healthy persons.

Methods: To gain further insight into the pathogenesis of this disease, gene expression was analysed in peripheral blood mononuclear cells from 25 patients with CFS diagnosed according to the Centers for Disease Control criteria and 25 normal blood donors matched for age, sex, and geographical location, using a single colour microarray representing 9522 human genes. After normalisation, average difference values for each gene were compared between test and control groups using a cutoff fold difference of expression $\geqslant$ 1.5 and a p value of 0.001. Genes showing differential expression were further analysed using Taqman real time polymerase chain reaction (PCR) in fresh samples.

Results: Analysis of microarray data revealed differential expression of 35 genes. Real time PCR confirmed differential expression in the same direction as array results for 16 of these genes, 15 of which were upregulated (ABCD4, PRKCL1, MRPL23, CD2BP2, GSN, NTE, POLR2G, PEX16, EIF2B4, EIF4G1, ANAPC11, PDCD2, KHSRP, BRMS1, and GABARAPL1) and one of which was downregulated (IL-10RA). This profile suggests T cell activation and perturbation of neuronal and mitochondrial function. Upregulation of neuropathy target esterase and eukaryotic translation initiation factor 4G1 may suggest links with organophosphate exposure and virus infection, respectively.

Conclusion: These results suggest that patients with CFS have reproducible alterations in gene regulation.

Chronic fatigue syndrome (CFS)/myalgic encephalomyelitis is a disease that is characterised by severe and debilitating fatigue, sleep abnormalities, impaired memory and concentration, and musculoskeletal pain.[1] In the Western world, the population prevalence is estimated to be in the order of 0.5%.[1 2] Although CFS is now recognised as a genuine clinical entity, a considerable research effort has failed to identify quantifiable parameters that consistently exhibit abnormal results in well documented cases. Therefore, the pathological basis for CFS remains poorly understood. Although there is no known aetiology and no known diagnostic marker, a large number of diverse factors such as viral infection; immune activation; exposure to toxins, chemicals, and pesticides; stress; hypotension; lymphocyte abnormalities; and neuroendocrine dysfunction have been proposed as factors in the pathogenesis of CFS.[3]

> "Although chronic fatigue syndrome is now recognised as a genuine clinical entity, a considerable research effort has failed to identify quantifiable parameters that consistently exhibit abnormal results in well documented cases"

Three previous reports have studied gene expression in the peripheral blood of patients with CFS.[4–6] Although there was little agreement between these studies as to the genes identified, only one used quantitative polymerase chain reaction (PCR) to confirm the initial findings[4] and the initial method in this study was differential display. To address this discrepancy and to investigate the hypothesis that abnormalities of gene regulation occur in CFS, we studied gene expression in peripheral blood mononuclear cells (PBMC) of

Table 1 Patient information including summary of aspects used for the CFS case definition and scores for physical fatigue, mental fatigue, anxiety, and depression

Clinical parameter	N
Sex	9 male/16 female
Mean age	40.6 years
Mean duration of disease	2.3 years
CFS began with flu-like illness	15
Impaired memory	22
Impaired concentration	21
Sore throat	17
Myalgia	20
Arthralgia	13
Headache	19
Unrefreshing sleep	21
Post exertional malaise	23
Tender lymphadenopathy	18
Autonomic features	20
Atopic features	13
Physical fatigue (Chalder) score (most severe, 21)	Mean, 17.2; range, 12–21
Mental fatigue (Chalder) score (most severe, 12)	Mean, 9.28; range, 5–12
Anxiety score (HAD) (most severe, 21)	Mean, 9.88; range, 3–18
Depression score (HAD) (most severe, 21)	Mean, 7.96; range, 1–20

CFS, chronic fatigue syndrome; HAD, Hospital Anxiety and Depression.

patients with CFS and normal blood donors using a microarray, and used Taqman real time PCR to confirm those genes identified as being differentially expressed

....

Abbreviations: CFS, chronic fatigue syndrome; NBS, National Blood Service; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain reaction

Table 2 Genes showing a significant ≥1.5 fold change between cases and controls in microarray experiments

GenBank accession number	Gene name (mRNA)	Gene symbol	Fold difference (array)	p Value	Taqman assay ID	Fold difference (PCR)	p Value
NM_020325	ATP binding cassette, subfamily D (ALD), member 4, tv-4	**ABCD4**	3.398	0.00257	Hs00245340_m1	1.825	0.0019
NM_002741	Protein kinase C-like 1	**PRKCL1**	2.288	0.00438	Hs00177028_m1	2.669	1.09×10^{-5}
NM_021134	Mitochondrial ribosomal protein L23	**MRPL23**	2.175	0.00135	Hs00221699_m1	4.032	1.25×10^{-6}
NM_001558	Interleukin 10 receptor α	**IL10RA**	0.252	0.00225	Hs00387004_m1	0.395	2.34×10^{-12}
NM_006110	CD2 antigen (cytoplasmic tail) binding protein 2	**CD2BP2**	2.311	0.00158	Hs00272036_m1	2.411	2.6×10^{-4}
NM_000177	Gelsolin (amyloidosis, Finnish type)	**GSN**	2.141	0.00105	Hs00609276_m1	1.83	6.23×10^{-7}
NM_006702	Neuropathy target esterase	**NTE**	2.877	0.00043	Hs00198648_m1	6.409	1.31×10^{-12}
NM_002696	Polymerase (RNA) II (DNA directed) polypeptide G	**POLR2G**	2.264	0.00372	Hs00275738_m1	3.407	3.69×10^{-6}
NM_004813	Peroxisomal biogenesis factor 16, tv-1	**PEX16**	3.004	0.00213	Hs00191337_m1	1.758	0.0126
NM_015636	Eukaryotic translation initiation factor 2B, subunit 4δ, tv-1	**EIF2B4**	2.414	0.00125	Hs00248984_m1	1.882	1.8×10^{-5}
NM_004953	Eukaryotic translation initiation factor 4γ1, tv-5	**EIF4G1**	3.081	0.00177	Hs00191933_m1	2.964	7.63×10^{-13}
NM_016476	APC11 anaphase promoting complex subunit 11 homologue	**ANAPC11**	3.278	0.00219	Hs00212858_m1	2.366	3.5×10^{-6}
NM_002598	Programmed cell death 2, tv-1	**PDCD2**	2.052	0.00266	Hs00751277_sH	1.887	1.3×10^{-4}
NM_003685	KH-type splicing regulatory protein (FUSE binding protein 2)	**KHSRP**	2.366	0.00139	Hs00269352_m1	1.64	0.0022
NM_015399	Breast cancer metastasis suppressor 1	**BRMS1**	2.246	0.00219	Hs00363036_m1	1.598	0.003
NM_031412*	GABA(A) receptor associated protein-like 1	**GABARAPL1**	2.358	0.00046	Hs00744468_s1	1.838	0.0097
NM_004655	Axin 2 (conductin, axil)	AXIN2	0.351	0.00056	Hs00610344_m1	0.780	0.023
NM_019051*	Mitochondrial ribosomal protein L50	MRPL50	0.427	0.00409	Hs00745120_s1	0.815	0.0019
NM_005103*	Fasciculation and elongation protein ζ1 (zygin I), tv-1	FEZ1	0.336	0.00007	Hs00192714_m1	3.485	2.3×10^{-6}
NM_002093	Glycogen synthase kinase 3β	GSK3B	2.294	0.00238	Hs00275656_m1	0.763	0.0015
NM_005098	Musculin (activated B cell factor 1)	MSC	0.374	0.00121	Hs00231955_m1	1.118	0.036
NM_138325	Paired basic amino acid cleaving system 4, tv-6	PACE4	0.473	0.00414	Hs00159844_m1	2.093	1.2×10^{-4}
NM_003584	Dual specificity phosphatase 11	DUSP11	0.366	0.00005	Hs00186058_m1	1.725	0.134
NM_002483	Carcinoembryonic antigen related cell adhesion molecule 6	CEACAM6	0.301	0.00048	Hs00366002_m1	1.585	0.182
NM_019051*	Mitochondrial ribosomal protein L50	MRPL50	0.427	0.00409	Hs00747929_m1	1.136	0.178
NM_030575	Hypothetical protein MGC10334	MGC10334	2.584	0.00118	Hs00257998_s1	1.724	0.067
NM_031412*	GABA(A) receptor associated protein-like 1	GABARAPL1	2.358	0.00046	Hs00740588_mH	0.93	0.127
NM_007175	Chromosome 8 open reading frame 2	C8orf2	2.554	0.00206	Hs00200360_m1	1.198	0.052
NM_032118	Hypothetical protein FLJ12953	FLJ12953	1.931	0.00309	Hs00259557_m1	1.139	0.203
NM_004879	Etoposide induced 2.4 mRNA	EI24	0.45	0.00181	Hs00747550_m1	1.03	0.085
NM_079834	Secretory carrier membrane protein 4	SCAMP-4	2.8	0.00069	Hs00365263_m1	1.586	0.173
NM_022145	Leucine zipper protein FKSG14	FKSG14	0.345	0.00205	Hs00259557_m1	1.212	0.345
NM_005103*	Fasciculation and elongation protein ζ1 (zygin I), tv-1	FEZ1	0.336	0.00007	Hs00363763_m1	1.062	0.41
NM_003409	Zinc finger protein 161 homologue	ZFP161	0.415	0.00146	NA	NT	NT
NM_007075	JM5 protein	JM5	2.383	0.00172	NA	NT	NT
NM_005345	Heat shock 70 kDa protein 1A	HSPA1A	3.198	0.00003	NA	NT	NT
NM_017616	Hypothetical protein FLJ20004	FLJ20004	2.679	0.00237	NA	NT	NT
NM_020663	Ras homologue gene family, member J	ARHJ	2.277	0.00346	NA	NT	NT

mRNA transcripts identified by array and differential expression confirmed by real time PCR are shown in bold.
The table also shows confirmatory Taqman assay numbers (Applied Biosystems UK) and fold changes by real time PCR.
*Transcript variants of particular genes.
NA, not available; NT, not tested; PCR, polymerase chain reaction.

between the groups. Sixteen genes were thus confirmed as having an expression profile associated with the CFS.

METHODS
Subject enrolment
Patients with CFS (n = 25) were enrolled from the Dorset CFS service in South East England. These cases were diagnosed according to the criteria of Fukuda and colleagues.[2] Additional clinical information was recorded and is presented in table 1. This includes measurements of physical and mental fatigue using the Chalder Fatigue Scale[7] and measurements of anxiety and depression using the Hospital Anxiety and Depression scales.[8] None of these patients had undergone previous treatment for psychiatric disorders. Patients were sampled at two time points, six months apart, between which their symptoms did not vary significantly; the first sample from each patient was used for microarray analysis whereas the second was used for real time PCR. This approach provides an additional safeguard against attaching particular importance to genes that may be differentially expressed at a single time point, but not reproducibly.

Normal blood donors were enrolled from the East Dorset division of the National Blood Service (NBS); 25 age and sex matched normal blood donors were used as a comparison group for the microarray part of the study, and 21 normal blood donors (age and sex matched as a group) were used as a comparison group for the real time PCR part of the study.

The NBS restricts donors to those who fulfil the following criteria: aged between 17 and 59 years; have not given blood in the previous 16 weeks; are not currently suffering from an infection; are not pregnant; are not currently taking (or within three months of taking) antibiotics, steroids, or antidepressants; have not had hepatitis, jaundice, body piercing, acupuncture, or blood transfusion in the past year; do not have two family members who suffered from Creutzfeldt-Jakob Disease; are not known to be positive for human immunodeficiency virus, hepatitis B or C; are not currently or previously abusers of injecting or body building drugs; are not post-vaccination; and do not suffer a chronic illness including malaria. Patients and controls gave written consent according to the guidance of the ethics committees of both the East Dorset NBS, the Royal Brompton and Harefield

NHS Trusts, and the National Heart and Lung Institute. The human experimentation guidelines of the US Department of Health and Human Services were followed in our study.

Sample collection and processing

A 20 ml sample of blood was immediately placed in cell preparation tubes containing density gradient solution and EDTA (BD Biosciences, Manchester, UK). PBMCs were isolated by density gradient centrifugation. Total RNA was extracted using Trizol (Invitrogen, Carlsbad, California, USA), washed in phosphate buffered saline, and the quality and amount confirmed by microspectrophotometry (Nanodrop, Rockland, Delaware, USA). Total RNA samples had an absorbance ratio (A260/280) of 1.85–1.95. A 20 ml sample of peripheral blood is estimated to contain a total of approximately 15×10^6 PBMCs and buffy coat from this sample yielded 10–25 µg total RNA, which was shipped to Nimblegen, USA, at room temperature in ethanol, for array testing. Total RNA was converted to double stranded cDNA by the SuperScript Choice System (Invitrogen) with an oligo dT primer containing the T7 RNA polymerase promoter sequence (5'-GGCCAGTGAATTGTAATACGACTCACTATAGG GAGGCGG-T24-3'). A 15 µg aliquot of total RNA was converted into cDNA. In vitro transcription was used to produce biotin labelled cRNA from cDNA using the Ambion MEGAscript T7 kit (Ambion, Austin, Texas, USA). Before hybridisation, cRNA was fragmented to an average size of 50–200 bp by incubation in 100mM potassium acetate, 30mM magnesium acetate, and 40mM Tris/acetate at 94℃ for 35 minutes. Fragmentation was checked by gel electrophoresis in 1% agarose.

Microarray design and analysis

A custom microarray was manufactured by Nimblegen (Madison, Wisconsin, USA) using maskless array synthesis (http://www.nimblegen.com). The human genes on this design (n = 9522) were selected from the *Homo sapiens* entries in the RefSeq collection of sequences as of August 2002. Each gene was compared with all others using the BLAST program to remove redundancies. Ten probe pairs for each target were selected from the 3' 1 kb of each target. Probes were spaced evenly over the length of the target region (≤1 kb), so that the exact spacing depended on the length of the target sequence. Each probe was 24 nucleotides in length. For each perfect match probe there was also a mismatch probe, which differed by a single nucleotide.

Labelled cRNA was hybridised to the oligonucleotide probes on the microarray. After washing, arrays were stained with streptavidin–cy3 conjugate (Amersham Biosciences, Piscataway, New Jersey, USA) for 25 minutes at room temperature, followed by washing and a blow dry step using high pressure grade 5 Argon (Badger Welding, Madison, Wisconsin, USA). Slides were scanned using a GenePix 4000B microarray scanner (Axon Instruments, Union City, California, USA), and the feature intensities extracted from the TIF files were calculated by the scanner software using a proprietary application developed at NimbleGen (Madison, Wisconsin, USA).[9] This application calculates mean signal intensities for the pixels that define each feature (3 × 3 grid of pixels). The intensities for each gene are calculated by taking the mean of the intensities for the perfect match probes specific to each target minus the mean of the intensity of the mismatch probes. Probes that differed from the mean for the set by more than 3 SD were removed from the set and the mean recalculated. Average differences (recalculated mean) were used for subsequent analysis.

Data analysis was performed using BRB ArrayTools version 3.02 (Molecular Statistics and Bioinformatics Section, National Cancer Institute, Bethesda, Maryland, USA) developed by Dr R Simon and A Peng (http://linus.nci.nih.gov/ BRB-ArrayTools.html). Average difference values were normalised to median over the array. The data were filtered so that only those genes that were adequately measured on 75% of the arrays were included. A class comparison protocol was used to identify genes whose degree of expression differed significantly by ⩾ 1.5 fold between the two groups. This consisted of a multivariate permutation test, which was computed based on 1000 random permutations using the following parameters: nominal significance level = 0.001; confidence level of false discovery rate assessment = 50%; maximum allowed number of false positive genes = 10; maximum allowed proportion of false positive genes = 0.1. Values for differentially expressed genes were used to cluster all 50 subjects using Genepilot software (http://www.genepilot. com) (TG Services, El Sobrante, California, USA).


Figure 1 Hierarchical clustering experiment of differentially expressed gene profiles among patients with chronic fatigue syndrome (CFS; n = 25) and normal persons (n = 25) identified by analysis in BRB Array Tools. The figure was generated using Genepilot software. Each column represents the expression profile for each of the 35 genes. Each row represents a single gene, with its GenBank accession number to the right hand side of the figure. Coloured pixels represent the magnitude of the response for any gene. Shades of red and green represent induction and repression, respectively, relative to the mean value for each respective gene among the normal persons. This figure shows a cluster of 18 subjects (from P29–P9) consisting of predominantly patients with CFS (n = 17) and one normal person, who have a similar profile of expression of these 35 genes. P, patients; C, controls.

Figure 2 (A) Bar chart showing the fold difference in gene expression between test and control groups by microarray (shaded) and real time polymerase chain reaction (solid black) for 16 genes that are differentially expressed in chronic fatigue syndrome (CFS). (B) Bar chart showing the mean relative quantity of mRNA transcripts in test (shaded) and control (solid black) groups for 16 genes that are differentially expressed in CFS. Error bars indicate the standard deviation from the mean in each case. All values for the mean relative quantity mRNA transcript are shown on the left y axis, except those for NTE and EIF4G1, which are shown on the right y axis.

Taqman real time PCR

Taqman real time PCR (Applied Biosystems, Foster City, California, USA) was used to confirm the importance of genes identified by array experiments in the same group of CFS cases (n = 17) and a different group of normal controls (n = 21); the controls were age and sex matched. cDNA was prepared from total RNA using the random hexamer method of reverse transcription, according to the instructions of the kit manufacturer (Applied Biosystems, Warrington, UK). Experiments were performed in triplicate in a custom 384 well low density array format using the ABI PRISM 7900HT instrument (Applied Biosystems) incorporating 38 target

gene assays (including three instances where two assays were used for a single gene to include transcript variants) (table 2) along with endogenous controls, namely: HMBS (hydroxymethylbilane synthase), HPRT-1 (hypoxanthine phosphoribosyltransferase 1), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), and eukaryotic 18S rRNA. Fluorogenic probes were 5′ labelled with 6-carboxyfluorescein (FAM) and 3′ labelled with MGB non-fluorescent quencher. Reactions were performed in a 1 µl reaction volume in Taqman Universal PCR Mastermix (Applied Biosystems UK). For each card channel (48 PCR reactions), 50 ng total RNA from PBMCs converted to cDNA was used as inoculum. Fluorescent signal detection used "ROX" as the internal passive reference dye.

The inoculum (100 µl) was a mixture of Taqman universal PCR master mix (Applied Biosystems) (50 µl), RNase/DNase free sterile water (45 µl), and cDNA (5 µl). Cycling times and temperatures were as follows. Initial denaturation was carried out for 10 minutes at 95℃, followed by 40 cycles of denaturation at 95℃ for 15 seconds and combined primer annealing/extension at 60℃ for one minute. Data was displayed using SDS 2.1 software (Applied Biosystems). GAPDH gave the least variable results in all samples and was used as the endogenous reference control. The threshold cycle (Ct) for each gene/sample pair was compared with a calibrator sample and a ΔCt value used to calculate a relative quantity of gene expression compared with the calibrator. RQ values were finally normalised to GAPDH expression. The F test for equality of standard deviations was used to compare mean RQ values for each gene in test versus control groups.

RESULTS
CFS disease phenotype
All 25 patients with CFS were diagnosed according to the Centers for Disease Control criteria of Fukuda et al.[2] Table 1 summarises the patient and clinical details. Our study included patients with CFS whose disease was severe and necessitated bed rest for much of the day, and also several patients whose disease was of a milder nature (table 1).

Microarray analysis
Analysis of microarray data identified 35 genes that showed significantly different expression in patients with CFS compared with normal controls (table 2). Hierarchical clustering of subjects on the basis of their degree of expression of these 35 genes revealed a cluster of 18 subjects, comprising 17 CFS patients and one normal person, whose expression profiles were very similar but distinctly different from the other patients and controls (fig 1). However, this patient cluster did not differ significantly with regard to other clinical variables shown in table 1, so that we were unable to explain this clustering.

Taqman real time PCR
TaqMan real time PCR analysis was used to confirm the importance of genes that were identified using microarray analysis. Significantly different expression, with the same profile as in gene arrays, was confirmed for 16 of 33 genes in the 17 patients tested. This method revealed upregulation of 15 genes and downregulation of one gene (table 2). Figure 2 illustrates the concurrent fold difference in gene expression between test and control groups for the 16 differentially expressed genes for both microarray and real time PCR analysis. The standard deviation from the mean is also shown in fig 2B and provides an indirect measure of the probable reproducibility of differential expression for each gene. In general, the standard deviation of these 16 genes in normal persons is very much lower than in patients with CFS, except for IL-10RA, in which the opposite is the case.

Table 3 Chronic fatigue syndrome associated genes: chromosomal location, expression, subcellular localisation, and function

GenBank accession number	Gene name (mRNA)	Gene symbol*	Chromosomal location	Expression	Subcellular localisation	Gene function
NM_020325	ATP binding cassette, subfamily D (ALD), member 4, tv-4	ABCD4	14q24.3	Ubiquitous	Peroxisomal membrane	ALDP expression
NM_002741	Protein kinase C-like 1	PRKCL1	19p13.1–p12	Ubiquitous	Cytoplasm	Regulation of cell motility
NM_021134	Mitochondrial ribosomal protein L23	MRPL23	11p15.5	Widely expressed	Mitochondrial matrix	Protein biosynthesis
NM_001558	Interleukin 10 receptor α	IL10RA	11q23.3	–	Unknown	Cytokine signalling
NM_006110	CD2 antigen (cytoplasmic tail) binding protein 2	CD2BP2	16p12.1	–	Unknown	–
NM_000177	Gelsolin (amyloidosis, Finnish type)	GSN	9q33.3	–	Unknown	Severing and capping of actin
NM_006702	Neuropathy target esterase	NTE	19p13.3–p13.2	Nervous system	Plasma membrane	Neurodegenerative disease
NM_002696	Polymerase (RNA) II (DNA directed) polypeptide G	POLR2G	11q13.1	Nervous system	Nucleus	Transcription from Pol II
NM_004813	Peroxisomal biogenesis factor 16, tv-1	PEX16	11p11.11	–	Peroxisomal membrane	Peroxisomal biogenesis
NM_015636	Eukaryotic translation initiation factor 2B, subunit 4δ, tv-1	EIF2B4	2p23.3	Ubiquitous	Mitochondrion	Initiation of translation
NM_004953	Eukaryotic translation initiation factor 4γ, 1, tv-5	EIF4G1	3q27–qter	Ubiquitous	Mitochondrion	Initiation of translation
NM_016476	APC11 anaphase promoting complex subunit 11 homologue	ANAPC11	17q25.3	Brain, heart, pancreas, lung	Nucleus	Ubiquitin ligase activity
NM_002598	Programmed cell death 2, tv-1	PDCD2	6q27	Ubiquitous	Cytoplasm	Apoptosis and regulation of cell proliferation
NM_003685	KH-type splicing regulatory protein (FUSE binding protein 2)	KHSRP	19p13.3	Nervous system	Nucleus	Neurone specific splicing of the N1 exon of SRC; assembly of other proteins
NM_015399	Breast cancer metastasis suppressor 1	BRMS1	14q13.1	Brain	Unknown	–
NM_031412[2]	GABA(A) receptor associated protein-like 1	GABARAPL1	12p12.3	Ubiquitous	Unknown	–

Table 3 provides information on the chromosomal location, expression, subcellular localisation, and function of these 16 genes. Although these genes do not fit neatly into known metabolic pathways, several broad themes are apparent. For example, T cell activation and neuronal and mitochondrial function.

DISCUSSION

In our present study, we studied transcript profiles from patients with CFS and from sex and age matched normal controls from the same area of South East England. The expression of 16 genes was significantly different in patients compared with controls in both microarray analysis and real time PCR. These genes may be important in the pathogenesis of CFS and can be grouped according to immune, neuronal, mitochondrial, and other functions that have particular relevance to our present knowledge of the epidemiology of CFS (table 4). Our present study has certain parallels with two published studies in this area, summarised in table 4.

T cell activation is suggested by upregulation of CD2BP2 and downregulation of IL-10RA[10–12]; in addition, PRKCL1 plays a role in the immune response. Genes that are active in the immune response have been found to be differentially expressed in all studies of gene expression in CFS (table 4). Furthermore, genes that are crucial for T cell activation[10] have also been found to be upregulated in all three studies, namely: CD2BP2 and IL-10RA (present study); moesin and cathepsin C[4]; ITGA and NFATC3.[5] These findings are consistent with previous work showing that patients with CFS have evidence of immune activation, such as increased numbers of activated T cells and cytotoxic T cells, and raised circulating cytokine concentrations.[3] [13–19]

Table 4 Possible mechanisms of disease in CFS based on three gene expression studies, each on patients with CFS and normal controls

Mechanism	Present study	Powell and colleagues[4]	Vernon and colleagues[5]
	Microarray (9522 genes)/qPCR; 25 CFS; 25 normal	Differential display/qPCR; 7 CFS; 4 normal	Filter array (1764 genes); 5 CFS; 17 normal
T cell activation	CD2BP2, IL-10RA	Moesin, CTSC	ITGA, NFATC3
Immune response	PRKCL1	TNF, MAIL	IL-8, CMRF35, ICAM2, ITGB, IER2, PLA2G2A, LCP-1, PRKCL
Neurone	PRKCL1, GSN, KHSRP, NTE, GABARAPL1		HD, PRKCL, ataxin, ADRA2A, DCTN1
Mitochondrion	EIF4G1, EIF2B4, MRPL23	SLC25A16, MCFP	
Skeletal muscle	GSN		DCTN1
Thyroid	GSN	THRAP2, SLC25A16	GDC
Cell cycle	ANAPC11	MAD1L1	
Apoptosis	PDCD2		
Transcription	POLR2G, BRMS1	RCOR3, POLR1B	
Peroxisome	ABCD4, PEX16		

CSF, chronic fatigue syndrome; qPCR, quantitative polymerase chain reaction.

A neuronal component is suggested by the upregulation of PRKCL1, NTE, GSN, GABARAPL1, KHSRP, and EIF2B4. Protein kinase C family members are implicated in various psychiatric and affective disorders, and have been implicated in previous gene studies of CFS.[5] NTE is a target for organophosphates and chemical warfare agents, both of which may precipitate CFS,[20] on the basis of a neuropathy resulting from inactivation of serine esterase activity.[21] GSN regulates cell growth and plays a role in amyloidosis (Finnish type), which may result in dysfunction of neurones, skeletal muscle, and thyroid gland.[22 23] GABARAPL1 is a microtubule associated anchor protein with increased expression in neuronal cells.[24] KHSRP facilitates splicing of the N1 exon of the SRC protooncogene in neuronal but not other cells.[25] EIF2B4 is a mitochondrial translation initiation factor and one of the EIF2B family, within which mutations have been shown to be associated with central nervous system hypomyelination and encephalopathy.[26] Powell and colleagues[4] have reported upregulation of an EIF2B3 gene homologue (BQ580379). These findings are interesting in that abnormalities in the white matter of the frontal lobes have been found in patients with CFS using magnetic resonance imaging and have been suggested to account for the cognitive defect in CFS.[27] Neuronal gene involvement in CFS has also been reported by Vernon and colleagues.[5]

Mitochondrial involvement is suggested by the upregulation of EIF2B4, EIF4G1 (see above), and MRPL23. Mitochondrial gene upregulation has also been reported by Powell et al.[4]

The cell cycle is implicated by upregulation of ANAPC11, which regulates the onset of anaphase by mediation of degradation of mitotic cyclins. Powell and colleagues[4] reported upregulation of MAD1L1, which prevents the onset of anaphase until all chromosomes are aligned at the metaphase plate.

''The upregulation of EIF4G1 identified in our present study may represent a common host response to persistent infection with several different viruses''

Transcriptional perturbation is suggested by the upregulation of POLR2G and BRMS1. Powell and colleagues[4] reported the upregulation of genes homologous with POLR1B (BQ580386) and RCOR3 (BQ580388), which are each involved in transcriptional regulation.

Upregulated peroxisomal function is suggested by the upregulation of ABCD4 and PEX16, which may suggest enhanced defence to oxidative stress in CFS. Oxidative stress has already been suggested as a disease mechanism in CFS.[28 29]

Persistent virus infection is a recognised feature of CFS, which is interesting in the light of our finding of upregulation of EIF4G1 transcript variant 5, a mitochondrial translation initiation factor. Whistler and colleagues[6] have also reported this finding in patients with CFS who have rapid (?triggered by virus infection) as compared with insidious onset. EIF4G1 is a component of the protein complex, EIF4F, which is crucial in translation through its involvement in the recognition of the mRNA cap, ATP dependent unwinding of 5' terminal secondary structure, and recruitment of mRNA to the ribosome.[30] Various viruses have developed strategies to divert EIF4G1 from its utilisation by the cellular machinery to facilitate production of viral proteins.[30] The best characterised example is that of poliovirus,[31 32] but this has also been demonstrated to occur with coxsackie virus,[33] rhinoviruses,[34] rotavirus,[35] influenza virus,[36] adenovirus,[37] vesicular stomatitis virus,[38] and human immunodeficiency virus 1.[39] Therefore, the upregulation of EIF4G1 identified in our present study

Take home messages

- Sixteen genes were differentially expressed in patients with chronic fatigue syndrome compared with normal controls, as assessed by microarray and quantitative polymerase chain reaction
- The involvement of genes from several disparate pathways suggests a complex pathogenesis involving T cell activation and abnormalities of neuronal and mitochondrial function
- These results suggest possible molecular bases for the recognised contributions of organophosphate exposure and virus infection

may represent a common host response to persistent infection with several different viruses. The vulnerability of EIF4G1 to virus modification may have particular importance for the development of CFS after an acute virus infection.[40]

In conclusion, we report the differential expression of 16 human genes in patients with CFS compared with normal controls. The involvement of genes from several disparate pathways suggests a complex pathogenesis involving T cell activation and abnormalities of neuronal and mitochondrial function, and suggests possible molecular bases for the recognised contributions of organophosphate exposure and virus infection, respectively.

. . . .

Authors' affiliations
N Kaushik, J R Kerr, Department of Paediatric Infectious Diseases, St Mary's Campus, Imperial College, 2nd Floor, Medical School Building, Norfolk Place, London W2 1PG, UK
D Fear, The Randall Centre, New Hunt's House, King's College London, Guy's Campus, London SE1 1UL, UK
S C M Richards, C R McDermott, Dorset CFS Service, Wareham, Dorset, UK
E F Nuwaysir, Nimblegen Systems Inc, 1 Science Court, Madison, WI 53711, USA
P Kellam, Department of Infection, Windeyer Institute of Medical Sciences, Royal Free and University College School of Medicine, London W1T 4JF, UK
T J Harrison, Department of Medicine, Windeyer Institute of Medical Sciences
R J Wilkinson, Wellcome Trust Centre for Research in Clinical Tropical Medicine, Faculty of Medicine, Imperial College London, London W2 1PG, UK
D A J Tyrrell, CFS Research Foundation, 2 The Briars, Rickmansworth, Hertfordshire WD3 6AU, UK
S T Holgate, MRC Department of Immunopharmacology, University of Southampton, Southampton SO16 6YD, UK

REFERENCES
1 A report of the CFS/ME working group. London: Department of Health, January 2002. (http://www.doh.gov.uk).
2 Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994;121:953–9.

3 **Komaroff AL**, Buchwald D. Chronic fatigue syndrome; an update. *Annu Rev Med* 1998;**49**:1–13.
4 **Powell R**, Ren J, Lewith G, et al. Identification of novel expressed sequences, upregulated in the leucocytes of chronic fatigue syndrome patients. *Clin Exp Allergy* 2003;**33**:1450–6.
5 **Vernon SD**, Unger ER, Dimulescu IM, et al. Utility of the blood for gene expression and biomarker discovery in chronic fatigue syndrome. *Dis Markers* 2002;**18**:193–9.
6 **Whistler T**, Unger ER, Nisenbaum R, et al. Integration of gene expression, clinical and epidemiologic data to characterise chronic fatigue syndrome. *J Transl Med* 2003;**1**:10–18.
7 **Chalder T**, Berelowitz G, Pawlikowska T, et al. *J Psychosom Res* 1993;**37**:147–53.
8 **Reeves WC**, Lloyd A, Vernon SD, et al. International chronic fatigue syndrome study group. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. *BMC Health Serv Res* 2003;**3**:25.
9 **Nuwaysir EF**, Huang W, Albert TJ, et al. Gene expression analysis using oligonucleotide arrays produced by maskless photolithography. *Genome Res* 2002;**12**:1749–55.
10 **Chu P**, Pardo J, Zhao H, et al. Systematic identification of regulatory proteins critical for T cell activation. *J Biol* 2003;**2**:21.
11 **Kofler M**, Heuer K, Zech T, et al. Recognition sequences for the GYF domain reveal a possible spliceosomal function of CD2BP2. *J Biol Chem* 2004;**279**:28292–7.
12 **Izquierdo M**, Cantrell DA. T-cell activation. *Trends Cell Biol* 1992;**2**:268–71.
13 **Chao CC**, Janoff EN, Hu SX, et al. Altered cytokine release in PBMC cultures from patients with the chronic fatigue syndrome. *Cytokine* 1991;**3**:292–8.
14 **MacDonald KL**, Osterholm MT, LeDell KH, et al. A case control study to assess possible triggers and cofactors in chronic fatigue syndrome. *Am J Med* 1996;**100**:548–54.
15 **Rasmussen AK**, Nielsen H, Andersen V, et al. Chronic fatigue syndrome—a controlled cross sectional study. *J Rheumatol* 1994;**21**:1527–31.
16 **Patarca-Montero R**, Antoni M, Fletcher MA, et al. Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors. *Appl Neuropsychol* 2001;**8**:51–64.
17 **Moss RB**, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. *J Clin Immunol* 1999;**19**:314–16.
18 **Penttila IA**, Harris RJ, Storm P, et al. Cytokine dysregulation in the post-Q-fever fatigue syndrome. *QJM* 1998;**91**:549–60.
19 **Kerr JR**, Barah F, Mattey DL, et al. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. *J Gen Virol* 2001;**82**:3011–19.
20 **Khan F**, Kennedy G, Spence VA, et al. Peripheral cholinergic function in humans with CFS, Gulf war syndrome and with illness following organophosphate exposure. *Clin Sci (Lond)* 2004;**106**:183–9.
21 **O'Callaghan JP**. Neurotoxic esterase: not so toxic? *Nat Genet* 2003;**33**:437–8.
22 **McGough AM**, Staiger CJ, Min JK, et al. The gelsolin family of actin regulatory proteins: modular structures, versatile functions. *FEBS Lett* 2003;**552**:75–81.
23 **Low PA**, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease. *Muscle Nerve* 2003;**27**:646–61.
24 **Nemos C**, Mansuy V, Vernier-Magnin S, et al. Expression of gec1/GABARAPL1 versus GABARAP mRNAs in human: predominance of gec1/GABARAPL1 in the central nervous system. *Brain Res Mol Brain Res* 2003;**119**:216–19.
25 **Min H**, Turck CW, Nikolic JM, et al. A new regulatory protein, KSRP, mediates exon inclusion through an intronic splicing enhancer. *Genes Dev* 1997;**11**:1023–36.
26 **Leegwater PA**, Pronk JC, van der Knaap MS. Leukoencephalopathy with vanishing white matter: from magnetic resonance imaging pattern to five genes. *J Child Neurol* 2003;**18**:639–45.
27 **Lange G**, DeLuca J, Maldjian JA, et al. Brain MRI abnormalities exist in a subset of patients with chronic fatigue syndrome. *J Neurol Sci* 1999;**171**:3–7.
28 **Chaudhuri A**, Behan PO. In vivo magnetic resonance spectroscopy in chronic fatigue syndrome. *Prostaglandins Leukot Essent Fatty Acids* 2004;**71**:181–3.
29 **Smirnova IV**, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. *Mol Cell Biochem* 2003;**248**:93–5.
30 **Byrd MP**, Zamora M, Lloyd RE. Generation of multiple isoforms of eukaryotic translation initiation factor 4GI by use of alternate translation initiation codons. *Mol Cell Biol* 2002;**22**:4499–511.
31 **Prevot D**, Darlix J-L, Ohlmann T. Conducting the initiation of protein synthesis: the role of EIF4G. *Biol Cell* 2003;**95**:141–56.
32 **Kuyumcu-Martinez NM**, Van Eden ME, Younan P, et al. Cleavage of poly(A)-binding protein by poliovirus 3C protease inhibits host cell translation: a novel mechanism for host translation shutoff. *Mol Cell Biol* 2004;**24**:1779–90.
33 **Thompson SR**, Sarnow P. Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor EIF4G is cleaved. *Virology* 2003;**315**:259–66.
34 **Glaser W**, Triendl A, Skern T. The processing of eIF4GI by human rhinovirus type 2 2A(pro): relationship to self-cleavage and role of zinc. *J Virol* 2003;**77**:5021–5.
35 **Groft CM**, Burley SK. Recognition of EIF4G by rotavirus NSP3 reveals a basis for mRNA circularisation. *Mol Cell* 2002;**9**:1273–83.
36 **Burgui I**, Aragon T, Ortin J, et al. PABP1 and eIF4GI associate with influenza virus NS1 protein in viral mRNA translation initiation complexes. *J Gen Virol* 2003;**84**:3263–74.
37 **Cuesta R**, Xi Q, Schneider RJ. Adenovirus-specific translation by displacement of kinase Mnk1 from cap-initiation complex eIF4F. *EMBO J* 2000;**19**:3465–74.
38 **Connor JH**, Lyles DS. Vesicular stomatitis virus infection alters the EIF4F translation initiation complex and causes dephosphorylation of the EIF4E binding protein 4e-BP1. *J Virol* 2002;**76**:10177–87.
39 **Perales C**, Carrasco L, Ventoso I. Cleavage of EIF4G by HIV-1 protease: effects on translation. *FEBS Lett* 2003;**533**:89–94.
40 **Chia JK**. Diverse aetiologies for the chronic fatigue syndrome. *Clin Infect Dis* 2003;**36**:671–2.